🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Olivier Mir

Amgen (United States)

ORCID: 0000-0002-6761-4002

Also affiliated with Institut Gustave Roussy

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study”.

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study

European Journal of Cancer(2021)10.1016/j.ejca.2021.03.039

N/A

1.3DataRank · unranked

47 citations

Antoîne Italiano, Emannuelle Bompas, María Rios, Nicolas Penel, Olivier Mir +18 more

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib

Annals of Oncology(2023)10.1016/j.annonc.2023.04.006

N/A

1.2DataRank · unranked

42 citations

Sebastian Bauer, David Gómez-Peregrina, Yoon‐Koo Kang, Robin L. Jones, Piotr Rutkowski +13 more

Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

Cancer(2021)10.1002/cncr.33618

N/A

0DataRank · unranked

229 citations

Anna Maria Frezza, Jean‐Yves Blay, Elizabeth H. Baldini, Sylvie Bonvalot, Judith V.M.G. Bovée +52 more